SO062PREDICTING ONE YEAR MORTALITY IN END-STAGE-RENAL DISEASE PATIENTS STARTING DIALYSIS; MODEL DEVELOPMENT AND VALIDATION

Twenty diabetics with end-stage renal disease who had never previously received dialysis treatment were treated with continuous ambulatory peritoneal dialysis for periods of two to 36 months (average, 14.5). Intraperitoneal administration of insulin achieved good control of blood sugar Even though creatinine clearance decreased significantly (P = 0.001), contro of blood urea nitrogen and serum creatinine was adequate. Hemoglobin and serum albumin levels increased significantly (P = 0.005 and 0.04 respectively). Similarly, there was a significant increase in serum triglycerides and alkaline phosphatase (P = 0.02 and 0.05). Blood pressure became normal without medications in all but one of the patients. Retinopathy, neuropathy, and osteodystrophy remained unchanged. Peritonitis developed once in every 20.6 patient-months a rate similar to that observed in nondiabetics. The calculated survival rate was 92 per cent at one year; the calculated rate of continuation on ambulatory peritoneal dialysis was 87 per cent.

Download Full-text

Depression, Perception of Illness and Mortality in Patients with End-Stage Renal Disease

The International Journal of Psychiatry in Medicine ◽

10.2190/d7va-fweu-jn5y-td3e ◽

1991 ◽

Vol 21 (4) ◽

pp. 343-354 ◽

Cited By ~ 123

Author(s):

Rolf A. Peterson ◽

Paul L. Kimmel ◽

Carol R. Sacks ◽

Mary Louise Mesquita ◽

Samuel J. Simmens ◽

...

Keyword(s):

Renal Disease ◽

End Stage Renal Disease ◽

Early Recognition ◽

Additional Measure ◽

Treatment Of Depression ◽

Severity Scores ◽

One Year ◽

Stage Renal Disease ◽

End Stage

A role of depression in affecting outcome in patients with end stage renal disease (ESRD) has been suggested but few have assessed psychological parameters and medical factors thought to influence survival simultaneously and prospectively. To assess whether depression or perception of illness influences survival in patients treated for ESRD, we prospectively evaluated fifty-seven patients with ESRD treated with hemodialysis (HD, n = 43) or continuous ambulatory peritoneal dialysis (CAPD, n = 14). Patients were interviewed and completed the Beck Depression Inventory (BDI) and the Illness Effects Questionnaire (IEQ). An ESRD severity coefficient was used to measure chronic illness severity. A cognitive item subset of the BDI (CDI) was used as an additional measure of depression. One and two years later, records were examined to determine survival. When initial results of the assessment of survivors and non-survivors were compared, at one year follow-up, there were no differences in mean age, duration of dialysis, severity scores, BDI or IEQ scores. The initial mean CDI scores in the group of non-survivors, however, were significantly greater than the scores in the survivor group. At two year follow-up, CDI scores were significantly different between groups, and were significant in a hazards regression. Disease severity, age and duration of dialysis were also significantly related to mortality at two year follow-up. We conclude cognitive depression is an important, early, indicator of grave prognosis in patients treated for ESRD. Early recognition of and therapeutic efforts directed toward the treatment of depression might modify outcome in ESRD patients.

Download Full-text

An Investigation on the One-year Rate of Arteriovenous Fistula Failure and Its Related Factors in Patients with End-stage Renal Disease; an Experience in Golestan Province of Iran

Nephro-Urology Monthly ◽

10.5812/numonthly.117420 ◽

2021 ◽

Vol In Press (In Press) ◽

Author(s):

Fariba Esmaeil Mosharafi ◽

Maryam Montazeri ◽

Saeid Amirkhanlou

Keyword(s):

Renal Disease ◽

Arteriovenous Fistula ◽

End Stage Renal Disease ◽

Related Factors ◽

History Of ◽

Golestan Province ◽

One Year ◽

The One ◽

Stage Renal Disease ◽

End Stage

Background: Aortic arch calcification (AAC) is very common in hemodialysis patients and is associated with cardiovascular events and the incidence of arteriovenous fistula (AVF) failure. In order to predict the prognosis of patients, a study was conducted to determine the annual failure rate of AVF and its related factors. Methods: This cross-sectional study was performed on 145 patients with end-stage renal disease (ESRD) who were AVF candidates, visiting a referral center in Golestan province of Iran. After the insertion of intravenous arterial fistulas, posterior-anterior chest x-rays were captured, and the grafts were classified by a radiologist. Patients were followed for one year, and the rates of fistula failure (FF) and cardiovascular mortality were recorded. Finally, the data were entered into SPSS 19 software and analyzed by the Chi-square test. Results: Of 112 patients followed up for one year, 56.2% were men. During the one-year follow-up period, 5.3% of the patients developed arteriovenous FF, and this event was more common in men, but the difference was not statistically significant. The majority of the AVF candidates had a history of diabetes and hypertension, but no association was found between the one-year FF rate and these two diseases. Nearly 7.7% of the patients had grade III calcification, but no significant relationship was observed between the AAC grade and AVF failure rate. Conclusions: The rate of one-year FF was higher among ESRD patients with a history of chronic kidney diseases. Our results also demonstrated that the mortality rate is higher in patients with a high degree of AAC and patients with medical history (cardiovascular disease and diabetes).

Download Full-text

Faculty Opinions recommendation of One-Year Outcomes of Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727355434.793529487 ◽

2017 ◽

Author(s):

John Augoustides

Keyword(s):

Aortic Valve ◽

Aortic Valve Replacement ◽

Renal Disease ◽

Valve Replacement ◽

End Stage Renal Disease ◽

Transcatheter Aortic Valve Replacement ◽

Transcatheter Aortic Valve ◽

One Year ◽

Stage Renal Disease ◽

End Stage

Download Full-text

One-Year Mortality Rates in US Children with End-Stage Renal Disease

American Journal of Nephrology ◽

10.1159/000380828 ◽

2015 ◽

Vol 41 (2) ◽

pp. 121-128 ◽

Cited By ~ 23

Author(s):

Blanche M. Chavers ◽

Julia T. Molony ◽

Craig A. Solid ◽

Michelle N. Rheault ◽

Allan J. Collins

Keyword(s):

Peritoneal Dialysis ◽

Renal Disease ◽

End Stage Renal Disease ◽

Mortality Rates ◽

Transplant Recipients ◽

Dialysis Patients ◽

One Year ◽

Stage Renal Disease ◽

End Stage ◽

Esrd Patients

Background/Aims: Few published data describe survival rates for pediatric end-stage renal disease (ESRD) patients. We aimed to describe one-year mortality rates for US pediatric ESRD patients over a 15-year period. Methods: In this retrospective cohort study, we used the US Renal Data System database to identify period-prevalent cohorts of patients aged younger than 19 for each year during the period 1995-2010. Yearly cohorts averaged approximately 1,200 maintenance dialysis patients (60% hemodialysis, 40% peritoneal dialysis) and 1,100 transplant recipients. Patients were followed for up to 1 year and censored at change in modality, loss to follow-up, or death. We calculated the unadjusted model-based mortality rates per time at risk, within each cohort year, by treatment modality (hemodialysis, peritoneal dialysis, transplant) and patient characteristics; percentage of deaths by cause; and overall adjusted odds of mortality by characteristics and modality. Results: Approximately 50% of patients were in the age group 15-18, 55% were male, and 45% were female. The most common causes of ESRD were congenital/reflux/obstructive causes (55%) and glomerulonephritis (30%). One-year mortality rates showed evidence of a decrease in the number of peritoneal dialysis patients (6.03 per 100 patient-years, 1995; 2.43, 2010; p = 0.0263). Mortality rates for transplant recipients (average 0.68 per 100 patient-years) were consistently lower than the rates for all dialysis patients (average 4.36 per 100 patient-years). Conclusions: One-year mortality rates differ by treatment modality in pediatric ESRD patients.

Download Full-text

Development and Validation of a New LC–MS/MS Analytical Method for Direct-Acting Antivirals and Its Application in End-Stage Renal Disease Patients

European Journal of Drug Metabolism and Pharmacokinetics ◽

10.1007/s13318-019-00584-6 ◽

2019 ◽

Vol 45 (1) ◽

pp. 89-99 ◽

Cited By ~ 1

Author(s):

Faten Farouk ◽

Dina Wahba ◽

Sherif Mogawer ◽

Shaimaa Elkholy ◽

Ahmed Elmeligui ◽

...

Keyword(s):

Renal Disease ◽

Analytical Method ◽

End Stage Renal Disease ◽

Direct Acting Antivirals ◽

Stage Renal Disease ◽

Direct Acting ◽

End Stage ◽

Development And Validation

Download Full-text

Outcomes of membranous and proliferative lupus nephritis – analysis of a single-centre cohort with more than 30 years of follow-up

Rheumatology ◽

10.1093/rheumatology/keaa103 ◽

2020 ◽

Vol 59 (11) ◽

pp. 3314-3323 ◽

Cited By ~ 2

Author(s):

Filipa Farinha ◽

Ruth J Pepper ◽

Daniel G Oliveira ◽

Thomas McDonnell ◽

David A Isenberg ◽

...

Keyword(s):

Lupus Nephritis ◽

Renal Disease ◽

End Stage Renal Disease ◽

Patient Survival ◽

Renal Survival ◽

Single Centre ◽

Proliferative Lupus Nephritis ◽

One Year ◽

Stage Renal Disease ◽

End Stage

Abstract Objectives To compare membranous lupus nephritis (MLN) and proliferative lupus nephritis (PLN) with respect to survival, demographic, clinical and laboratory characteristics; and to investigate predictors of renal and patient survival. Methods Single-centre retrospective observational study. Patients with biopsy-proven PLN, MLN and mixed lupus nephritis were included. Groups were compared using appropriate statistical tests and survival was analysed through the Kaplan-Meier method. Cox regression analysis was performed to investigate predictors of renal and patient survival. Results A total of 187 patients with biopsy-proven lupus nephritis (135 with PLN, 38 with MLN and 14 with mixed LN) were followed for up to 42 years (median 12 years). There was a higher proportion of MLN amongst Afro-Caribbeans than amongst Caucasians (31% vs 15%, P = 0.010). Patients with MLN had significantly lower anti-dsDNA antibodies (P = 0.001) and higher C3 levels (P = 0.018) at diagnosis. Cumulative renal survival rates at 5, 10, 15 and 20 years were 91, 81, 75 and 66% for PLN and 100, 97, 92 and 84% for MLN, respectively (P = 0.028). Cumulative patient survival at 5, 10, 15 and 20 years was 94, 86, 80 and 76%, with no difference between PLN and MLN. Urinary protein-creatinine ratio above 42 mg/mmol and eGFR below 76 ml/min/1.73 m2, one year after the diagnosis of LN, were the strongest predictors of progression to end-stage renal disease. eGFR below 77 ml/min/1.73 m2, at one year, development of end-stage renal disease and Afro-Caribbean ethnicity were associated with higher mortality. Conclusion Patients with MLN and PLN differ significantly regarding serological profiles and renal survival, suggesting different pathogenesis. Renal function at year one predicts renal and patient survival.

Download Full-text